Role of enhanced half-life factor VIII and IX in the treatment of haemophilia-Reference-Cited by-同舟云学术

Role of enhanced half-life factor VIII and IX in the treatment of haemophilia

Published:2015-03-07 Issue:6 Volume:169 Page:768-776
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mahdi Ali J.¹,Obaji Samya G.¹,Collins Peter W.¹

Affiliation:

1. Department of Haematology; University Hospital of Wales and School of Medicine Cardiff University; Cardiff UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13360/fullpdf

Reference43 articles.

1. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs;Agersø;Haemophilia,2012

2. Population pharmacokinetics of recombinant factor IX: implications for dose tailoring;Björkman;Haemophilia,2013

3. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years;Björkman;European Journal of Clinical Pharmacology,2009

4. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring;Björkman;Journal of Thrombosis and Haemostasis,2010

5. Bleeding phenotype with various Bay 94-9027 dosing regimens: subanalyses from the Protect VIII Study;Boggio;Blood (ASH Annual Meeting Abstracts),2014

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Joint health and pain in the changing hemophilia treatment landscape;Expert Review of Hematology;2024-07-15

2. Health care costs and resource use of managing hemophilia A: A targeted literature review;Journal of Managed Care & Specialty Pharmacy;2023-06

3. Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice;Scientific Reports;2022-11-22

4. Early stage clinical trials for the treatment of hemophilia A;Expert Opinion on Investigational Drugs;2022-11-02

5. Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States;Journal of Blood Medicine;2022-09